<DOC>
	<DOCNO>NCT01563263</DOCNO>
	<brief_summary>This confirmatory , randomize , placebo-controlled , multi-center , double-blinded phase II/III study . The study population consist male female intensive care unit ( ICU ) patient need mechanical ventilation 48 hour , age 18 80 year .</brief_summary>
	<brief_title>Confirmatory Phase II/III Study Assessing Efficacy , Immunogenicity Safety IC43</brief_title>
	<detailed_description>This confirmatory , randomize , placebo-controlled , multi-center , double-blinded phase II/III study . The study population consist male female intensive care unit ( ICU ) patient need mechanical ventilation 48 hour , age 18 80 year . Eight-hundred patient enrol approximately 50 study center . Informed consent ( i.e. , patient patient 's legally authorize representative ) waiver obtain accord regional requirement prior study related procedure . Patients randomize receive either IC43 100 mcg placebo receive first vaccination Day 0 . The second vaccination apply Day 7 . In case ICU discharge occur Day 7 , immunization do hospital ward .</detailed_description>
	<mesh_term>Pseudomonas Infections</mesh_term>
	<criteria>male female patient admit intensive care unit ( ICU ) need mechanical ventilation least 48 hour , age 18 80 year Visit 0 write informed consent waiver accord national regulation childbearing potential negative pregnancy test Sequential Organ Failure Assessment ( SOFA ) &lt; 4 Day 0 Patients &lt; 6 month post organ transplantation readmission ICU current total hospital stay Day 0 patient admit ICU within 2 day surgery patient admit ICU due trauma elective surgery Day 28 first vaccination</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>IC43</keyword>
	<keyword>Pseudomonas Aeruginosa</keyword>
	<keyword>mechanically ventilated ICU patient</keyword>
	<keyword>ICU patient</keyword>
</DOC>